Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Deciding Which Cancer-Related Fatigue Assessment Tool to Use Just Got Much Easier

May 16, 2022
By Lisa Sprod, PhD, MPH
Publication
Article
OncologyONCOLOGY Vol 36, Issue 5
Volume 36
Issue 5
Pages: 278-279

Lisa Sprod, PhD, MPH, provides perspective on a cancer-related fatigue assessment tools.

Lisa Sprod, PhD, MPH, provides perspective on Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research Recommendations

TABLE 1. Category 1 Validated Patient-Reported Cancer-Related Fatigue Assessment Instruments

TABLE 1. Category 1 Validated Patient-Reported Cancer-Related Fatigue Assessment Instruments

Cancer-related fatigue (CRF) is most often evaluated using patient-reported tools, making it subjective in nature. In addition, CRF is multidimensional and often a comorbid condition occurring with mood disorders, pain, and sleep disturbance, among others. Numerous tools have been developed to assess CRF, yet it remains the most common and persistent symptom and/or adverse effect resulting from cancer and its treatment, often lasting many years. In a large multicenter study (n > 3000), Wang et al found that moderate to severe fatigue is common in cancer survivors during active treatment and beyond.1 Other investigators have found that up to 99% of patients with cancer report CRF; and in up to one-third of survivors, fatigue persisted for as long as 10 years after the end of therapy.2

TABLE 2. Category 2 Validated Patient-Reported Cancer-Related Fatigue Assessment Instruments

TABLE 2. Category 2 Validated Patient-Reported Cancer-Related Fatigue Assessment Instruments

Despite the high prevalence of CRF, it is still thought to be underreported and undertreated, perhaps in part due to confusion about how to best assess it. With so many survivors of cancer negatively affected by CRF, investigators have focused their efforts on attempting to determine the most effective ways to reduce its impact. Exercise, psychological interventions, and pharmacological treatments have proven to offer some improvement in CRF. As a coauthor on a meta-analysis conducted to determine which intervention was most effective of the 3 listed above, I examined the wide variety of tools used to assess CRF. As an investigator, I have spent countless hours deciding on the best tool to use in my research. Assessment tools vary in their length; the ideal time in which to use them; the recall period; the constructs evaluated; and their sensitivity, reliability, and validity. All of these considerations may leave investigators and clinicians unsure of the best tool for their particular need.

TABLE 3. Category 3 Validated Patient-Reported Cancer-Related Fatigue Assessment Instruments

TABLE 3. Category 3 Validated Patient-Reported Cancer-Related Fatigue Assessment Instruments

The authors of the accompanying article have done a phenomenal job providing information that will aid investigators and clinicians in determining the best tool for their needs.3 Specifically, the article provides information that may clarify the best tool for assessing CRF based on factors such as the reason for assessment of CRF (clinical or research) and patient and clinician burden. This article provides a thorough overview of CRF, including prevalence, potential mechanisms, and common comorbidities. Next, the authors describe the challenges associated with choosing the appropriate tool and considerations one should make. With that backdrop, clinicians and investigators are able to utilize the comprehensive tables provided by the authors that categorize tools based on use for screening (Table 1), unidimensional measures (Table 2), or multidimensional measures (Table 3). Information on populations in which the tools have been validated, whether the tools have been translated and/or culturally adapted and validated, the number of items in each tool, the type of rating scales the tools use, the estimated completion time of the tools, and more is available. This article will be one I keep close at hand when reading articles that include CRF as an outcome, and I will certainly rely on it as a I choose CRF measures in my research. In addition, this article may serve as a model that inspires investigators and clinicians to comprehensively review other outcomes with multiple tools for assessment.

References

  1. Wang XS, Zhao F, Fisch MJ, et al. Prevalence and characteristics of moderate to severe fatigue: a multicenter study in cancer patients and survivors. Cancer. 2014;120(3):425-432. doi:10.1002/cncr.28434
  2. Schmidt ME, Hermann S, Arndt V, Steindorf K. Prevalence and severity of long-term physical, emotional, and cognitive fatigue across 15 different cancer entities. Cancer Med. 2020;9(21):8053-8061. doi:10.1002/cam4.3413
  3. Gentile D, Beeler D, Wang XS, et al. Cancer-related fatigue measures in integrative oncology: evidence for practice and research recommendations. ONCOLOGY (Williston Park). 2022;36(5):276-287.
Download Issue PDFDownload PDF
Articles in this issue

Deciding Which Cancer-Related Fatigue Assessment Tool to Use Just Got Much Easier
Deciding Which Cancer-Related Fatigue Assessment Tool to Use Just Got Much Easier
Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research Recommendations
Cancer-Related Fatigue Outcome Measures in Integrative Oncology: Evidence for Practice and Research Recommendations
Making Progress in PTCL: Significant Unmet Needs
Making Progress in PTCL: Significant Unmet Needs
Current Treatment of Peripheral T-cell Lymphoma
Current Treatment of Peripheral T-cell Lymphoma
Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell Carcinoma
Leukocytoclastic Vasculitis Induced by Immune Checkpoint Inhibition in a Patient With Advanced Renal Cell Carcinoma
Expert Commentary On The Product Profile Of Dostarlimab
Expert Commentary On The Product Profile Of Dostarlimab
CRISPR Patent Battle: Beautiful Science, Poor Public Policy
CRISPR Patent Battle: Beautiful Science, Poor Public Policy
Recent Videos
Related Content
Advertisement

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

Radhika Appaya;Sara A. Hurvitz, MD;Michal Jarzab;Montserrat Munoz Mateu;Erin Cobain;Jin Zhang;Arielle Medford;Alistair Ring;Priyanka Sharma, MD;Christian Schem, MD;Ionut Temciuc;Zheng Li;Juan Pablo Zarate;Denise A. Yardley, MD
June 26th 2025
Article


Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Creating a First-of-Its-Kind Integrative Oncology Program at City of Hope

Edward S. Kim, MD, MBA;Richard T. Lee, MD
March 18th 2024
Podcast

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.


This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.

Extranodal NK/T-Cell Lymphoma Misdiagnosed as Pulmonary Infection

ONCOLOGY Staff
June 25th 2025
Article

This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.


Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.


22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE

22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE

Radhika Appaya;Sherene Loi, MD, PhD;Erica Stringer-Reasor;Jean-Sebastien Frenel;Mattea Reinisch;Ruth M. O’Regan;Michelino De Laurentiis;Yeon Hee Park;Anne O’Dea;Yen-Shen Lu;Valeria Gonzalez;Melissa Gao;Sorcha Waters;Huilin Hu;Binghe Xu
June 24th 2025
Article


23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

Radhika Appaya;Nicholas McAndrew;Stephen Chia;Fabio Puglisi;Aditya Bardia, MD, MPH;Yann Izarzugaza;Christian Schem, MD;Binghe Xu;Fanny Le Du;Priyanka Sharma, MD;Karen Afenjar;Murat Akdere;Juan Pablo Zarate;Yogesh Chattar;Peter A. Fasching
June 23rd 2025
Article

Related Content
Advertisement

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

Radhika Appaya;Sara A. Hurvitz, MD;Michal Jarzab;Montserrat Munoz Mateu;Erin Cobain;Jin Zhang;Arielle Medford;Alistair Ring;Priyanka Sharma, MD;Christian Schem, MD;Ionut Temciuc;Zheng Li;Juan Pablo Zarate;Denise A. Yardley, MD
June 26th 2025
Article


Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.

Creating a First-of-Its-Kind Integrative Oncology Program at City of Hope

Edward S. Kim, MD, MBA;Richard T. Lee, MD
March 18th 2024
Podcast

Edward S. Kim, MD, MBA, and Richard T. Lee, MD discuss how integrative oncology techniques such as acupuncture have impacted patient quality of life at their practice.


This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.

Extranodal NK/T-Cell Lymphoma Misdiagnosed as Pulmonary Infection

ONCOLOGY Staff
June 25th 2025
Article

This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.


Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.


22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE

22 Efficacy and Safety of Ribociclib + Nonsteroidal Aromatase Inhibitor in Younger Patients With HR+/HER2− Early Breast Cancer in NATALEE

Radhika Appaya;Sherene Loi, MD, PhD;Erica Stringer-Reasor;Jean-Sebastien Frenel;Mattea Reinisch;Ruth M. O’Regan;Michelino De Laurentiis;Yeon Hee Park;Anne O’Dea;Yen-Shen Lu;Valeria Gonzalez;Melissa Gao;Sorcha Waters;Huilin Hu;Binghe Xu
June 24th 2025
Article


23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

23 Clinical Outcomes in Patients With HR+/HER2− Early Breast Cancer By Prior Systemic Treatment: A Subgroup Analysis of the NATALEE Trial

Radhika Appaya;Nicholas McAndrew;Stephen Chia;Fabio Puglisi;Aditya Bardia, MD, MPH;Yann Izarzugaza;Christian Schem, MD;Binghe Xu;Fanny Le Du;Priyanka Sharma, MD;Karen Afenjar;Murat Akdere;Juan Pablo Zarate;Yogesh Chattar;Peter A. Fasching
June 23rd 2025
Article

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.